Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has become an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). With its inclusion in international guidelines, understanding the practical aspects of integrating PSMA-RLT into clinical practice is crucial for oncologists and healthcare professionals managing prostate cancer patients.
PSMA-RLT: An Evolving Treatment Landscape
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a significant advancement in the management of prostate cancer. Specifically, [177Lu] Lu-PSMA-617 has emerged as an established treatment for metastatic castration-resistant prostate cancer (mCRPC) and is now incorporated into international guidelines. This therapy has demonstrated improved oncologic outcomes, including enhanced survival, progression-free survival, and biochemical response rates, as evidenced by landmark clinical trials such as VISION, TheraP, and PSMAfore1.
Patient Selection and Imaging Biomarkers
Appropriate patient selection is a critical factor for optimizing the efficacy and safety of PSMA-RLT. The selection process primarily relies on PSMA positron emission tomography (PET) imaging to confirm PSMA expression in tumor lesions and assess the overall disease burden. This imaging helps identify patients who are most likely to benefit from PSMA-RLT. Beyond imaging, a comprehensive multidisciplinary evaluation is essential to consider the patient's overall health, prior treatments, and potential comorbidities. While current selection criteria are well-defined, emerging imaging biomarkers are under investigation and may further refine patient selection in the future1.
Expanding Indications for PSMA-RLT
Initially established for heavily pretreated mCRPC, the evidence base for PSMA-RLT is expanding to include earlier stages of prostate cancer. Research is exploring its utility in taxane-naïve disease, metastatic hormone-sensitive prostate cancer (mHSPC), and even in neoadjuvant settings. This expansion suggests a broader potential role for PSMA-RLT across the prostate cancer treatment continuum, potentially offering new therapeutic avenues for patients at different disease stages1.
Practical Treatment Considerations and Toxicity Monitoring
Integrating PSMA-RLT into clinical practice requires careful attention to practical considerations. These include the logistical aspects of radionuclide administration, patient preparation, and post-treatment care. Given the nature of radioligand therapy, robust toxicity monitoring protocols are essential. Clinicians must be prepared to manage potential adverse events, which may include hematologic toxicities, xerostomia, and renal impairment, among others. Regular monitoring of blood counts, renal function, and salivary gland function is typically part of the treatment regimen to ensure patient safety and manage side effects proactively1.
Clinical Implications: Why this matters for clinical practice today
The growing evidence supporting PSMA-RLT underscores the need for oncologists to be well-versed in its application. For clinicians managing prostate cancer, understanding the nuances of patient selection, the practicalities of treatment delivery, and effective toxicity management is paramount. The shift towards considering PSMA-RLT in earlier disease stages means that referring oncologists should proactively identify suitable candidates and collaborate closely with nuclear medicine specialists. Establishing clear referral pathways and multidisciplinary team discussions will be key to ensuring patients receive timely and appropriate access to this evolving therapy, ultimately optimizing their treatment outcomes.
Limitations and Future Directions
While PSMA-RLT has demonstrated significant benefits, ongoing research continues to refine its application. Current limitations include the need for further investigation into optimal dosing schedules, combination therapies, and the long-term management of potential toxicities. Future directions for PSMA-RLT involve exploring its efficacy in combination with other systemic therapies, identifying predictive biomarkers beyond PSMA expression to further personalize treatment, and evaluating its role in very early-stage disease or as a consolidative therapy. Continued research will help to fully integrate PSMA-RLT into a comprehensive, individualized prostate cancer management strategy1.
- The Pivot PSMA-RLT is now an established treatment for mCRPC, with expanding evidence for earlier use in other prostate cancer settings.
- The Data Landmark trials (VISION, TheraP, PSMAfore) have demonstrated improved survival, progression-free survival, and biochemical response rates with [177Lu] Lu-PSMA-617.
- The Action Clinicians must prioritize appropriate patient selection via PSMA PET imaging and multidisciplinary evaluation, and understand practical treatment considerations and toxicity monitoring.
ART-2026-1196
·08/26
Drafted with AI assistance, reviewed and approved by the editorial team. This publication is intended for healthcare professionals, researchers, and life science industry professionals. Content is provided for informational and educational purposes only and does not constitute medical advice.
Science writer covering the frontier between basic research and clinical practice. I am interested in the moment a mechanism becomes a therapy, and everything that can go wrong in between.
Cite This Article
Aldrich M, Voss M. Navigating PSMA-RLT for prostate cancer: what clinicians need to know now. The Life Science Feed. Published August 27, 2026. Updated August 27, 2026. Accessed August 27, 2026. https://thelifesciencefeed.com/oncology/radioligand-therapy/practice/navigating-psma-rlt-for-prostate-cancer-what-clinicians-need-to-know-now.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources: published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Hennes D, Al-Khanaty A, Monna M, et al. Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide. Eur Urol Focus. 2026;S2405-4569(26)00110-0. doi:10.1016/j.euf.2026.06.014
